These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6153637)

  • 41. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanisms of lipopolysaccharide-induced protection against pseudomonas sepsis in granulocytopenic mice.
    Tegtmeier BR; Andersen BR
    Rev Infect Dis; 1983; 5 Suppl 5():S963-70. PubMed ID: 6419318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.
    Hatano K; Boisot S; DesJardins D; Wright DC; Brisker J; Pier GB
    Infect Immun; 1994 Sep; 62(9):3608-16. PubMed ID: 7520416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Opsonic activity of antisera to ribosomal vaccine fractions with live and formalinized Pseudomonas aeruginosa.
    Lieberman MM; Allen RC
    Can J Microbiol; 1986 Jun; 32(6):531-3. PubMed ID: 3089571
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibacterial immunity induced by ribosomal vaccines.
    Winston SH; Berry LJ
    J Reticuloendothel Soc; 1970 Jul; 8(1):13-24. PubMed ID: 4988339
    [No Abstract]   [Full Text] [Related]  

  • 46. Characterization of the 5' and 3' ends of the 16S ribonucleic acid from T 1 -ribonuclease treated 30S ribosomes.
    Santer M; Santer UV
    Biochemistry; 1972 Feb; 11(5):786-91. PubMed ID: 4551094
    [No Abstract]   [Full Text] [Related]  

  • 47. [Protective protein antigens of Pseudomonas aeruginosa].
    Edvabnaia LS; Zaĭdner IG; Makarenko TA; Bulk VF; Zhvanetskaia MI
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Nov; (11):18-23. PubMed ID: 3937389
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COMPOSITION OF BACTERIAL RIBOSOMAL RNA. HETEROGENEITY WITHIN A GIVEN ORGANISM.
    ARONSON AI; HOLOWCZYK MA
    Biochim Biophys Acta; 1965 Feb; 95():217-31. PubMed ID: 14293697
    [No Abstract]   [Full Text] [Related]  

  • 49. [Principle of constructing polyvalent Pseudomonas aeruginosa vaccines].
    Akatova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Feb; (2):56-60. PubMed ID: 84457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.
    Bruderer U; Cryz SJ; Schaad UB; Deusinger M; Que JU; Lang AB
    J Infect Dis; 1992 Aug; 166(2):344-9. PubMed ID: 1634805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pseudomonas aeruginosa ribosomal vaccine. A comparison of the immunogenicity of vaccines from two different serotypes.
    Lieberman MM
    Antibiot Chemother (1971); 1989; 42():193-202. PubMed ID: 2512837
    [No Abstract]   [Full Text] [Related]  

  • 52. Pseudomonas aeruginosa infection and vaccination in the rat.
    Kostiala AA
    J Med Microbiol; 1980 May; 13(2):201-12. PubMed ID: 6770090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Production and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. IV. The effect of immunization with Pseudomonas aeruginosa vaccine on the immune status of volunteer donors].
    Titova TI; Sidorova TN; Radkevich SA; Antsiferova NG; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Aug; (8):80-4. PubMed ID: 3933225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Requirement of the conformational stability of a Salmonella ribosomal vaccine for its mouse protection.
    Kita E; Oku D; Nishikawa F; Emoto M; Yasui K; Kashiba S
    FEMS Microbiol Immunol; 1991 Aug; 3(4):229-39. PubMed ID: 1931135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Active and passive immunity against Pseudomonas aeruginosa with a ribosomal vaccine and antiserum in C3H/HeJ mice.
    Lieberman MM; Ayala E
    J Immunol; 1983 Jul; 131(1):1-3. PubMed ID: 6408166
    [No Abstract]   [Full Text] [Related]  

  • 56. [Protective effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine in generalized chronic Pseudomonas aeruginosa infection in mice with cyclophosphamide-induced leukopenia].
    Vetkova LG; Zaĭtsev LG; Khasman EL; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):14-8. PubMed ID: 3085409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella.
    Eisenstein TK
    Infect Immun; 1975 Aug; 12(2):364-77. PubMed ID: 51007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    Matthews-Greer JM; Gilleland HE
    J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of the specificity of lipopolysaccharide antigens from seven Fisher's immunotypes of Pseudomonas aeruginosa, using ELISA technique.
    Trafny EA; Grzybowski J
    Acta Microbiol Pol; 1988; 37(2):191-204. PubMed ID: 2467530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.